Ana Maria Giménez-Arnau, EAACI 2022: A Phase 2b Study of Remibrutinib for Chronic Spontaneous Urticaria
Remibrutinib is an oral BTK inhibitor currently being investigated in a phase 2 trial in urticaria. It was a pleasure to talk with Prof. Ana Maria Giménez-Arnau (Hospital del Mar. IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain) around the safety findings from the long term extension of a phase 2b study of remibrutinib in chronic spontaneous urticaria patients.
The abstract ‘Long-term safety and tolerability of remibrutinib (LOU064) in Phase 2b study in chronic spontaneous urticaria patients.’ was presented at EAACI 2022, 1-3 July, 2022.
- What were the aims, design and eligibility criteria of the phase 2b study? (0:35)
- What were the safety findings of the study? (2:18)
- What makes this therapy so attractive compared to other treatment modalities for CSU? (8:38)
Disclosures: Ana Maria Giménez-Arnau discloses consulting for Novartis; receiving grant/ research support from Novartis; serving on advisory boards for Novartis; and receiving honoraria from Novartis.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EAACI Hybrid Congress 2022.
Share this Video
Related Videos In Dermatological Conditions
Melinda Gooderham, Dermatology Meeting News 2023: Abrocitinib efficacy in atopic dermatitis by baseline disease severity – findings from an interim analysis of JADE EXTEND
JADE-EXTEND (NCT03422822) is a phase 3 long-term extension study investigating the efficacy and safety of abrocitinib in atopic dermatitis. In this touchIMMUNOLOGY interview, we caught up with Dr. Melinda Gooderham (SKiN Centre for Dermatology, Ontario, Canada) around her interim analysis of JADE-EXTEND, looking at efficacy by baseline disease severity. The abstract ‘Influence of Baseline Disease […]
Melinda Gooderham, Dermatology Meeting News 2023: Deucravacitinib efficacy by baseline characteristic in moderate to severe plaque psoriasis
Deucravacitinib is an allosteric tyrosine kinase 2 inhibitor approved for the treatment of moderate to severe plaque psoriasis, a post-hoc analysis of the phase 3 POETYK PSO-1 and PSO-2 trials investigated the efficacy of deucravacitinib by baseline characteristics in this indication. touchIMMUNOLOGY were delighted to speak with Dr. Melinda Gooderham (SKiN Centre for Dermatology, Ontario, […]
William Damsky, Dermatology Meeting News 2023: A personalised approach to treating inflammatory skin diseases
Personalised medicine utilises biomarkers to predict patient outcomes and responses to treatment, ensuring that patients get the most effective treatment quicker. We were delighted to speak to Expert Faculty member Dr. William Damsky (Yale School of Medicine, New Haven, CT, USA) around the recent advances made in biomarkers and targeted therapies for inflammatory skin diseases, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!